Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
7.09
+0.04 (0.57%)
Dec 26, 2024, 10:29 AM EST - Market open
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for GLUE stock have an average target of 12.67, with a low estimate of 11 and a high estimate of 16. The average target predicts an increase of 78.70% from the current stock price of 7.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for GLUE stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 4 | 4 | 4 | 4 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | +55.15% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +55.15% | Sep 12, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +139.77% | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $16 | Buy | Reiterates | $16 | +125.67% | Jun 28, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +55.15% | May 22, 2024 |
Financial Forecast
Revenue This Year
26.17M
Revenue Next Year
15.56M
from 26.17M
Decreased by -40.56%
EPS This Year
-1.54
from -2.63
EPS Next Year
-1.53
from -1.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 36.1M | 54.6M | 81.9M | |||
| Avg | 26.2M | 15.6M | 31.8M | |||
| Low | 19.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 108.6% | 426.5% | |||
| Avg | - | -40.6% | 104.6% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.50 | -0.92 | -1.00 | |||
| Avg | -1.54 | -1.53 | -1.66 | |||
| Low | -1.55 | -1.83 | -2.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.